The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
OPDUALAG (Bristol-Myers Squibb Australia Pty Ltd)
Product name
OPDUALAG
Date registered
Evaluation commenced
Decision date
Approval time
221 (255 working days)
Active ingredients
nivolumab, relatlimab
Registration type
New combination
Indication
OPDUALAG is indicated for the treatment of patients with unresectable or metastatic melanoma who are at least 12 years old.